The Journal of Clinical Endocrinology & Metabolism · 2005 · 58 citations · 44 references
MedicineEndocrinologyGynecologyMenstrual DisordersReproductive EndocrinologyWomen's HealthMenstrual CycleUterine PathologyEndometrial Extracellular Matrix RemodelingEndometrial ProliferationGelatinase ActivityMatrix Metalloproteinase Gene ExpressionMatrix MetalloproteinasesTissue Explant Culture
Various matrix metalloproteinases (MMPs) participate in the menstrual breakdown of the human endometrium. MMP-9/gelatinase B is proposed as a major factor because it degrades many extracellular matrix constituents, including in the vasculature. Although globally under ovarian steroids control, endometrial MMP-9 seems expressed differently than other MMPs, and conflicting publications prevent a clear understanding of its regulation. We therefore quantified MMP-9 expression in the cycling human endometrium, defined its localization, and analyzed its regulation by estradiol and progesterone and by LEFTY-A/endometrial bleeding-associated factor in explant cultures. In fresh tissues, a major increase in MMP-9 mRNA expression occurred at menstruation, after a larger increase in LEFTY-A mRNA. MMP-9 was immunodetected in all cell types throughout the cycle, especially in foci of stromal cells during menstruation. MMP-9 synthesis by these cells was confirmed in cultured explants. In proliferative explants, ovarian steroids slightly decreased MMP-9 mRNA. They had no consistent effect on MMP-9 release in culture medium but strongly inhibited proMMP-9 activation. Addition of recombinant LEFTY-A to explants induced MMP-9 in most samples, a response prevented by ovarian steroids. We propose that endometrial MMP-9 activity is overall controlled by the ovarian steroids and locally adjusted through a network of modulators, including LEFTY-A.
44
William H. Rodgers, Lynn M. Matrisian, Linda C. Giudice et al. · Journal of Clinical Investigation · 1994 · 385 citations · Full text